This certification was awarded after FlowMetric met the rigorous training and testing requirements set out by IsoPlexis. FlowMetric can now provide Single-Cell Functional Proteomic services to its Pharmaceutical and Biotechnology customers to complement its decade-long expertise in developing and validating multi-parameter Flow Cytometry-based approaches for drug development.
“The FlowMetric team continually looks for new and powerful service offerings for our clients. The IsoPlexis platform delivers state-of-the-art proteomic analysis, enabling us to reveal the true functionality of cells,” said FlowMetric Chief Scientific Officer, Dr. Julie Bick, “Like Flow Cytometry, the IsoPlexis technology has applications across many areas of clinical research and will help our clients identify key biological drivers and ultimately accelerate their scientific research.”